Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Ageas, Eiffage, GlaxoSmithKline, UCB: Europe Equity Preview

May 6 (Bloomberg) -- The following companies’ shares may have unusual moves in European trading. Stock symbols are in parentheses.

The Stoxx Europe 600 Index lost 0.3 percent to 277.79. The Stoxx 50 Index fell 0.2 percent to 2,608.68. The Euro Stoxx 50 Index, a benchmark for nations using the euro, dropped 0.9 percent to 2,926.54.

Ageas (AGS BB): The insurer formerly known as Fortis said it will appeal a ruling by the Rotterdam District Court, which upheld a 576,000 euro ($837,000) fine levied by the Dutch market regulator. Ageas dropped 0.5 percent to 2.01 euros.

Corio NV (CORA NA): The largest Dutch real-estate company said first-quarter profit excluding items rose 18 percent as acquisitions and rent increases lifted revenue. Corio shares advanced 0.3 percent to 47.57 euros.

EDP-Energias de Portugal SA (EDP PL): Portugal’s biggest power company said first-quarter net income rose 11 percent to 342 million euros partly on higher output from wind energy projects. The stock dropped 1.1 percent to close at 2.67 euros.

Eiffage SA (FGR FP): The construction company said that first-quarter sales rose to 2.99 billion euros from 2.91 billion euros and that orders were in line with forecasts. Shares fell 1.4 percent to 44.77 euros.

GlaxoSmithKline Plc (GSK LN): Chief Executive Officer Andrew Witty said all options are open in the long term for the Viiv Healthcare Ltd. venture, which specializes in HIV treatments. The stock gained 0.3 percent to 1,310 pence.

Groupe Bruxelles Lambert SA (GBLB BB): The Belgian investment firm controlled by billionaires Albert Frere and Paul Desmarais reported first-quarter profit dropped to 11 million euros from 20.1 million euros a year earlier because of costs for unwinding derivatives. GBL retreated 0.1 percent to 66.61 euros.

Rexam Plc (REX LN): The world’s biggest beverage-can maker reported a 9 percent increase in first-quarter can sales volume outside North America as demand rose. The shares rose 0.5 percent to 385.4 pence.

UCB SA (UCB BB): The maker of the Cimzia rheumatoid arthritis medicine said Schwarz Vermoegensverwaltung GmbH & Co KG cut its stake to 2.97 percent of voting rights as of April 29 from 4.96 percent on Dec. 9. UCB decreased 0.6 percent to 31.12 euros.

Wendel (MF FP): The investment firm said first-quarter revenue was 1.44 billion euros, compared with a pro-forma 1.2 billion euros, and said growth is recovering in mature markets. The shares fell 1.3 percent to 81.97 euros.

To contact the reporter on this story: Jeff Sutherland in New York at

To contact the editor responsible for this story: Nick Baker at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.